Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.

Future oncology (London, England) - 1 Mar 2025

Costa Alessandro, Scalzulli Emilia, Bisegna Maria Laura, Breccia Massimo

Abstract excerpt

In the evolving therapeutic landscape of chronic myeloid leukemia (CML), asciminib stands out as a critical treatment option. Its ability to bind to and allosterically modulate the myristoyl pocket of BCR::ABL1 enables asciminib to effectively overcome resistance to conventional tyrosine kinase inhibitors (TKIs). Asciminib has shown significant cytogenetic and molecular responses in heavily pretreated patients,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Niacinamide

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 39936231
DOI: 10.1080/14796694.2025.2464494
PMCID: PMC11921165

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.PMID 39936231Read ↗

Asciminib for chronic myeloid leukaemia: Next questions.Semantic proximity Read ↗

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Semantic proximity Read ↗

Asciminib as a third line option in chronic myeloid leukemia.Semantic proximity Read ↗

Asciminib in chronic myeloid leukemia.Semantic proximity Read ↗

Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.Semantic proximity Read ↗

Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.Semantic proximity Read ↗

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.Semantic proximity Read ↗

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.Semantic proximity Read ↗

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.Semantic proximity Read ↗

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.Semantic proximity Read ↗

Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.Semantic proximity Read ↗

Advances of next-generation STAMP inhibitors in chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.